Role of Liposomal Anthracyclines in the Treatment of Multiple Myeloma
December 2004
in “
Seminars in oncology
”
TLDR Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
The document reviewed the role of liposomal anthracyclines in treating multiple myeloma (MM), comparing traditional regimens like VAD with newer combinations such as DVd (liposomal doxorubicin, vincristine, dexamethasone). Studies showed that DVd had similar efficacy to VAD but with fewer severe side effects, including less alopecia and neutropenia, and required fewer hospital visits. A phase II trial with 33 newly diagnosed MM patients using DVd showed an 88% response rate, including 12% complete remissions. Overall, liposomal anthracyclines appeared to improve the therapeutic index and safety profile for MM patients, particularly the elderly, though further studies were needed to optimize treatment regimens.
